Evaluation of perceptions, knowledge and compliance with guidelines in real-life practice: A survey on the under-treatment of hypercholesterolemia

Two-thirds (67.5%) of the patients in the SP group had been prescribed a statin, whereas only 30.1% of thePP group patients received statin therapy (p

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: Few studies have directly assessed suboptimal management of dyslipidemia in Turkey.

📊

Key Findings & Data:This study was conducted to assess patients’ understanding and perceptions of high cholesterol as well as physicians’ knowledge and awareness of lipid management strategies.Methods: This was a multicenter, observational study (ClinicalTrials.gov identifier: NCT02608645).

💡

Conclusion & Impact:Two-thirds (67.5%) of the patients in the SP group had been prescribed a statin, whereas only 30.1% of thePP group patients received statin therapy (p

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objective: Few studies have directly assessed suboptimal management of dyslipidemia in Turkey. This study was conducted to assess patients’ understanding and perceptions of high cholesterol as well as physicians’ knowledge and awareness of lipid management strategies.Methods: This was a multicenter, observational study (ClinicalTrials.gov identifier: NCT02608645). Consecutive patients admitted to the participating cardiology clinics who were at least 18 years of age and who had been classified in a secondary prevention (SP) group or a high-risk primary prevention (PP) group were enrolled. The study population included 1868 patients from 40 sites in Turkey. Two-thirds (67.5%) of the patients in the SP group had been prescribed a statin, whereas only 30.1% of thePP group patients received statin therapy (p

Özet

Amaç: Türkiye’de dislipideminin suboptimal yönetimini az sayıda çalışma doğrudan değerlendirmiştir. Bu çalışma, hastaların yüksek kolesterol algısını ve lipit yönetim stratejileri ile ilgili olarak hekimlerin kolesterol hakkındaki bilgi ve farkındalığını değerlendirmek amacıyla yapıldı.Yöntemler: Çalışma gözlemsel ve çok merkezli bir çalışmadır (ClinicalTrials.gov identifier: NCT02608645). En az 18 yaşında olan, kardiyoloji kliniklerine başvuran ikincil korunma (SK) grubunda ve çok yüksek, yüksek riskli birincil korunma (PK) grubundaki ardışık hastalar çalışmaya alındı. Çalışma popülasyonu, Türkiye’de 40 bölgeden 1868 hasta içermektedir. SK grubunda hastaların üçte ikisine (%67.5) statin verildi, PK hastalarının sadece %30.1’ine statin tedavisi verildi (p

🔖

Cite This Article

BİTEKER, M., ÇELİK, O., BEKAR, L., ÇİNİER, G., KAYIKÇIOĞLU, M., DOĞAN, V., BAŞARAN, Ö., KALÇIK, M., AKSAN, G., AKTAŞ, M., RENCÜZOĞULLARI, İ., ÖZLEK, B., ÖZLEK, E., ÇİL, C., ÖZDEMİR, İ. H., RESULZADE, M. M., AKAY, K. H., KARADENİZ, F. Ö., K, K. (2022). Evaluation of perceptions, knowledge and compliance with guidelines in real-life practice: A survey on the under-treatment of hypercholesterolemia. Türk Kardiyoloji Derneği Arşivi, Cilt: 47 - Sayı: 7, 599–608. https://ajindex.com/articles/632087

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (11)

Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413–9
Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700–7
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78
Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA. Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. J Am Coll Cardiol 2016;68:252–60
Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340–6
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016;37:2999–3058
Reiner Ž, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, et al; EUROASPIRE Investigators. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries-Findings from the EUROASPIRE IV survey. Atherosclerosis 2016;246:243–50
Ünüvar N, Mollahaliloglu S, Yardim N, Refik Saydam. Hygiene Center. School of Public Health, on behalf of The Ministry of Health of Turkey (MoH). Turkey Burden of Disease Study 2004. 1th ed. Ankara: MoH Publication; 2007. p. 4–8
Turkish Statistical Institute. National Health Report of 2014. Turkey in Statistics 2014. Publication No: 4380. Ankara; 2014. Available at: http://www.turkstat.gov.tr/. Accessed Sep 2, 2016
European Commission. Eurostat Death Statistics Report of 2011. Eurostat regional yearbook 2011. Luxemburg: Publications Office of the European Union; 2011. Available at: http:// ec.europa.eu/eurostat/. Accessed Se